BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference
BridgeBio Pharma (Nasdaq: BBIO), a biopharmaceutical company specializing in genetic diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Co-founder and CEO Neil Kumar, Ph.D., will deliver a presentation on Monday, January 13 at 7:30 am PT.
Investors and interested parties can access the live webcast through the 'Events & Presentations' section of BridgeBio's investor website. The presentation recording will remain available for 30 days following the event on the company's website.
BridgeBio Pharma (Nasdaq: BBIO), un'azienda biofarmaceutica specializzata nelle malattie genetiche, ha annunciato la sua partecipazione al 43掳 Annual J.P. Morgan Healthcare Conference che si terr脿 a San Francisco. Il co-fondatore e CEO Neil Kumar, Ph.D., terr脿 una presentazione Luned矛 13 gennaio alle 7:30 ora del Pacifico.
Gli investitori e le persone interessate possono accedere alla diretta streaming attraverso la sezione 'Eventi e Presentazioni' del sito web per investitori di BridgeBio. La registrazione della presentazione rimarr脿 disponibile per 30 giorni dopo l'evento sul sito dell'azienda.
BridgeBio Pharma (Nasdaq: BBIO), una compa帽铆a biofarmac茅utica especializada en enfermedades gen茅ticas, ha anunciado su participaci贸n en la 43陋 Conferencia Anual de Salud de J.P. Morgan en San Francisco. El cofundador y CEO Neil Kumar, Ph.D., realizar谩 una presentaci贸n el lunes 13 de enero a las 7:30 am PT.
Los inversores y las partes interesadas pueden acceder a la transmisi贸n en vivo a trav茅s de la secci贸n 'Eventos y Presentaciones' del sitio web para inversionistas de BridgeBio. La grabaci贸n de la presentaci贸n estar谩 disponible durante 30 d铆as despu茅s del evento en el sitio web de la empresa.
敫岆歆�氚旍澊鞓� 鞝滌暯 (Nasdaq: BBIO), 鞙犾爠 歆堩櫂鞚� 鞝勲鞙茧 頃橂姅 靸濍獏瓿淀暀 須岇偓,臧赌 靸岉攧霝�鞁滌姢旖旍棎靹� 鞐措Μ電� 鞝�43須� JP 氇贝 項姢旒�鞏� 旎嵓霟办姢鞐� 彀胳棳頃滊嫟瓿� 氚滍憸頄堨姷雼堧嫟. 瓿惦彊 彀诫鞛愳澊鞛� CEO鞚� 雼� 炜犽毳�, Ph.D.臧赌 1鞗� 13鞚� 鞗旍殧鞚� 鞓れ爠 7鞁� 30攵� PT鞐� 氚滍憸毳� 歆勴枆頃� 鞓堨爼鞛呺媹雼�.
韴瀽鞛愲摛瓿� 甏�鞁� 鞛堧姅 攵勲摛鞚� 敫岆歆�氚旍澊鞓� 韴瀽鞛� 鞗轨偓鞚错姼鞚� '鞚措菠韸� 氚� 氚滍憸' 靹轨厴鞚� 韱淀暣 霛检澊敫� 鞗轨簮鞀ろ姼鞐� 鞝戧芳頃� 靾� 鞛堨姷雼堧嫟. 氚滍憸 雲鬼檾電� 頄夓偓 鞚错泟 30鞚� 霃欖晥 須岇偓 鞗轨偓鞚错姼鞐愳劀 鞚挫毄 臧赌電ロ暕雼堧嫟.
BridgeBio Pharma (Nasdaq: BBIO), une entreprise biopharmaceutique sp茅cialis茅e dans les maladies g茅n茅tiques, a annonc茅 sa participation 脿 la 43e Conf茅rence Annuelle sur la Sant茅 de J.P. Morgan 脿 San Francisco. Le co-fondateur et PDG Neil Kumar, Ph.D., pr茅sentera un expos茅 le lundi 13 janvier 脿 7h30 PT.
Les investisseurs et les personnes int茅ress茅es peuvent acc茅der 脿 la diffusion en direct via la section '脡v茅nements et Pr茅sentations' du site Web pour les investisseurs de BridgeBio. L'enregistrement de la pr茅sentation restera disponible pendant 30 jours apr猫s l'茅v茅nement sur le site de l'entreprise.
BridgeBio Pharma (Nasdaq: BBIO), ein biopharmazeutisches Unternehmen, das auf genetische Erkrankungen spezialisiert ist, hat seine Teilnahme an der 43. j盲hrlichen J.P. Morgan Gesundheitskonferenz in San Francisco bekannt gegeben. Mitbegr眉nder und CEO Neil Kumar, Ph.D., wird am Montag, den 13. Januar um 7:30 Uhr PT einen Vortrag halten.
Investoren und Interessierte k枚nnen 眉ber den Bereich 'Veranstaltungen & Pr盲sentationen' auf der Investorenseite von BridgeBio auf den Live-Stream zugreifen. Die Aufzeichnung der Pr盲sentation wird 30 Tage nach der Veranstaltung auf der Website des Unternehmens verf眉gbar sein.
- None.
- None.
PALO ALTO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (鈥淏ridgeBio鈥� or the 鈥淐ompany鈥�), a new type of biopharmaceutical company focused on genetic diseases, today announced that co-founder and CEO, Neil Kumar, Ph.D., will present at the 43rd聽Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13 at 7:30 am PT.
To access the live webcast of BridgeBio鈥檚 presentation, please visit the 鈥淓vents & Presentations鈥� page within the Investors section of the BridgeBio website at聽. A replay of the webcast will be available on the BridgeBio website for 30 days following the event.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio鈥檚 pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit and follow us on , and .
BridgeBio Media Contact:
Vikram Bali
(650)-789-8220
FAQ
When is BridgeBio (BBIO) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch BridgeBio's (BBIO) J.P. Morgan Healthcare Conference presentation?
How long will BridgeBio's (BBIO) J.P. Morgan Conference presentation replay be available?
Who is presenting for BridgeBio (BBIO) at the 2025 J.P. Morgan Healthcare Conference?
